A Phase 1 Study of ABI‐009 (Nab‐sirolimus) in Combination With Temozolomide and Irinotecan in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors—A Children's Oncology Group Pediatric Early Phase Clinical Trial Network Study ADVL1514

ABSTRACT Background Nab‐sirolimus (ABI‐009, nab‐rapamycin; Aadi Bioscience Inc. [Aadi]) is a human albumin‐bound form of sirolimus nanoparticles, a potent mTOR inhibitor. This phase I trial was conducted to define dose‐limiting toxicities (DLT), maximum tolerated or recommended phase II dose (MTD/RP...

Повний опис

Бібліографічні деталі

Автори:	Stuart L. Cramer, Alyssa Terry Reddy, Charles Gene Minard, Stephan Voss, Elizabeth Fox, Xiaowei Liu, Kristina Denic, Joel M. Reid, Brenda J. Weigel
Формат:	Artigo
Мова:	Inglês
Опубліковано:	Wiley 2024-11-01
Серія:	Cancer Medicine
Предмети:	ABI‐009 Clinical trial nab‐rapamycin Pediatrics rapamycin
Онлайн доступ:	https://doi.org/10.1002/cam4.70376
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!